Inovio Pharmaceuticals: Pay

Inovio Pharmaceuticals paid its 3 named executives $3.3M in total in FY2025 (Dec). CEO Jacqueline E. Shea, Ph.D. was paid $1.6M of that.

Pay$100 in the stock at the end of FY21 → $3
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Jacqueline E. Shea, Ph.D.President and Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years
Michael SumnerM.D. Chief Medical Officer and Head of Development
FY2025 (Dec)
FY2024 (Dec)
2 years
Peter D. KiesChief Financial Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years

CEO pay against the pay peers

In FY2024 (Dec), the median CEO pay of the 5 peers with pay on file was $7.3M. The CEO of Inovio Pharmaceuticals was paid $2.1M, 72% below the median.

  1. 1TG Therapeutics
  2. 2Iovance Biotherapeutics
  3. 3Arcus Biosciences
  4. 4Replimune Group
  5. 5Agenus
  6. 6Inovio Pharmaceuticals
  7. 7Adaptimmune Therapeutics plcNot disclosed
  8. 8AlectorNot disclosed
  9. 9Allakos, Inc.Not disclosed
  10. 10Atara Biotherapeutics, Inc.Not disclosed
  11. 11ChemoCentryx, Inc.Not disclosed
  12. 12Deciphera PharmaceuticalsNot disclosed
  13. 13Epizyme, Inc.Not disclosed
  14. 14FibroGen, Inc.Not disclosed
  15. 15Forma Therapeutics, Inc.Not disclosed
  16. 16Heron Therapeutics, Inc.Not disclosed
  17. 17ImmunoGen, Inc.Not disclosed
  18. 18Karyopharm Therapeutics, Inc.Not disclosed
  19. 19MacrogenicsNot disclosed
  20. 20PureTech Health plcNot disclosed
  21. 21Seres TherapeuticsNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.